STAT

What’s in the cards for this year’s Nobel Prizes? Scientists are placing their bets

With the naming of the science Nobels fast approaching, polls, betting pools, and number crunching are in full swing.
Source: Hulton Archive/Getty Images

We’re not saying that discovering molecular drivers of cancer or cancer-causing genes doesn’t deserve the Nobel Prize in medicine or physiology. But for Dr. Brian Druker (whose work led to the targeted leukemia drug Gleevec), Dr. Dennis Slamon (Herceptin), and Mary-Claire King (the BRCA breast- and ovarian-cancer gene), 2019 is probably not their year to be summoned to Stockholm: The 2018 medicine Nobel honored immuno-oncology, and according to STAT’s Nobel crystal ball, cancer won’t win two years in a row.

With the naming of the science Nobels fast approaching — the medicine prize will be announced on Oct. 7, physics on Oct. 8, chemistry on Oct. 9 — polls, betting pools, and number crunching are in full swing, using approaches from toting up how many “predictor” prizes a scientist has won to calculating the periodicity of awards, meaning how many years pass before a specific subfield is honored again.

Past laureates, who get to submit nominations every year after though they usually are. As 2018 chemistry winner Frances Arnold of the California Institute of Technology said, “It’s not helpful to second-guess these things!”

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks